Prevalence of chronic kidney disease according to the CKD Epidemiology retrospective cohort study (Kirov city)

Abstract: The Study aimed to describe the available clinical and demographic characteristics of patients with CKD, to assess its occurrence by primary referral, and to analyze the clinical outcomes and current treatment of CKD. Material and methods: a retrospective cohort clinical study (protocol identification number: EVS-20-01115) was carried out. Electronic databases of medical records of patients undergoing outpatient treatment in the city of Kirov were examined. The inclusion criteria were diagnosed CKD or the presence of one or more changes in the structure or function of the kidneys associated with the development of CKD, determined for more than 3 months. Results: the occurrence of CKD in a cohort of outpatients from three medical institutions in the city of Kirov was 8.7% of the total number of outpatients. The structure of CKD stages demonstrated a low degree of detectability of CKD stages 1-2; CKD C2 and C3 were the most common (76.5%), while the prevalence of C1 was only 10.2%. Proteinuria was observed in 25% of patients with CKD, i.e. 1.83% of the number of patients in the database. Albuminuria was found rarely, in 7.39% of the total number of patients with abnormalities of the kidneys structure or function and 11.91% of patients with an established diagnosis of CKD. As a decrease in GFR was observed in 89.8% of CKD cases, and proteinuria in 25% of cases a decrease in GFR was a more frequent sign of CKD than proteinuria in the registered CKD cases by primary referral. Arterial hypertension, cerebrovascular diseases, and diabetes mellitus were widespread in patients with CKD. The most commonly prescribed drugs for CKD were aCEI and ARBs prescribed in 81.8% of cases. Conclusion: the analysis made clear the need for earlier detection of CKD C1-C2 and such diseases as diabetes mellitus and hypertension, which are the main causes of CKD (Trial is funded by Astra Zeneca company (LLC "AstraZeneca pharmaceuticals"), protocol EVS-20-01115).